Baker Bros. Advisors 13F: Adds $6.1M to DNTH Stake

Baker Bros. Advisors Boosts Stake in Dianthus Therapeutics

Baker Bros. Advisors expanded its investment in Dianthus Therapeutics, Inc. (NasdaqCM: DNTH) by acquiring an additional 62,405 shares during the period. The purchase marks a 7.9% increase for the firm, bringing its total ownership to 852,164 shares. According to a Form 13F filing with the SEC, the reported value of the expanded stake reached about $83.1 million. This filing reflects holdings as of the reporting period and may not represent the investor's current position today.

Inside the Portfolio Move

Prior to this purchase, Baker Bros. Advisors held 789,759 shares of the clinical-stage biotech company. The addition of 62,405 shares builds on the firm's existing exposure to the drug developer. Such portfolio adjustments offer a look at how specialized healthcare investors allocate capital across their preferred biotechnology names.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics traded around $97.48 recently, placing the stock well above its 200-day moving average of $79.04. The biotechnology company has experienced significant price movement, trading as low as $32.22 and reaching a peak of $117.88 over the past year. The broader market values the firm at approximately $5.4 billion.

Wall Street Analyst Coverage and Price Targets

Analyst sentiment surrounding the biotechnology company remains positive as development programs move forward. On October 15, 2026, HC Wainwright & Co. reiterated its Buy rating on the stock with a $158.00 price target. Earlier in the autumn, JP Morgan initiated coverage on September 11, 2026, with an Overweight rating and a $135.00 price target. Citigroup also started coverage on September 4, 2026, assigning a Buy rating and a $156.00 price target. During August, Truist Securities maintained a Buy rating while adjusting its target to $128.00 on August 6, 2026. On the same date, HC Wainwright & Co. maintained a Buy rating with a $158.00 target. Wedbush kept an Outperform rating on August 5, 2026, setting a $122.00 target, and Evercore ISI Group maintained an Outperform rating on August 3, 2026, with a $134.00 target.

Clinical Pipeline and Company Focus

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing new treatments for patients suffering from severe autoimmune diseases. Its lead candidate, claseprubart, is a monoclonal antibody engineered for extended half-life and high selectivity against the active C1s complement protein. The company is also advancing DNTH212, a bifunctional fusion protein designed to target plasmacytoid dendritic cells while suppressing B cell function.

What to Watch at Dianthus Therapeutics, Inc.

Investors tracking Dianthus Therapeutics will look toward the company's next earnings report, scheduled for November 5, 2026, for updates on its clinical pipeline and financial status. Additional SEC filings will show whether institutional investors continue adjusting their stakes as these drug candidates advance through clinical trials.